Osseon Therapeutics, Inc. announced that it has raised a $14 million round of equity financing led by a private investor. The proceeds will allow Osseon to expand its VCF device product line and continue to provide innovative devices for the treatment of vertebral compression fractures.

The new series of financing was completed in conjunction with existing investors who support Osseon's vision of becoming a preeminent spine company. "This infusion of capital will allow us to continue to develop our patented Orthopedic products and will propel us to the next level of commercial success," said CEO, Ron Clough.

About Osseon:

Osseon Therapeutics, Inc., headquartered in Santa Rosa, CA, is dedicated to developing and commercializing state of the art medical devices for minimally invasive treatments for degenerative bone and joint disease, including the treatment of vertebral compression fractures. The company's patented, steerable delivery system offers more treatment options than other commercial solutions as well as offering significant advantages in procedural efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers new, forward thinking solutions to patients suffering from these maladies, as well as to the physicians and medical facilities that treat them. Osseon's products are distributed globally.

For more information, visit our website at osseon.com.